Formerly known as Rib-X Pharmaceuticals, in October 2013 the firm changed its name to Melinta Therapeutics. In the Summer 2017, publicly traded firm Cempra Inc. - anti-infectives - and closely held Melinta Therapeutics Inc.mergied to create an anti-infectives company retaining the Melinta name and now trading on the Nasdaq. With facilites in New Haven, CT and Lincolnhsire. IL., the firm is developing broad spectrum antibiotics with superior coverage, safety and convenience to deliver new standards of care for patients with serious infections. The Company's Nobel Prize winning, innovative platform enables a unique understanding of how antibiotics combat infection and has generated an industry leading pipeline spanning all phases of research and clinical development. A small molecule drug discovery and development company, Melinta Therapeutics is dedicated to the discovery, development and commercialization of groundbreaking antibiotics to overcome drug-resistant, life-threatening infections. The need for new therapies for drug-resistant infections is widely recognized as one of the most serious public health issues facing the world today. To meet this need, Melinta Therapeutics is rapidly progressing its late-stage investigational antibiotic, delafloxacin, which is currently in Phase 3 development for acute bacterial skin and skin structure infections (ABSSSI) and uncomplicated gonorrhea. A key initiative at Melinta is to develop, through the application of Nobel Prize-winning science, a new class of antibiotics designed to overcome the drug-resistant ESKAPE pathogens known to cause serious hospital infections. The firm applied in November 2011 for IPO but withdrew. Expected to be consummated later in 2017, in August 201 ist was announced that Cempra (NASDAQ:CMEPT) wil merge with privately held Melinta. The name wil be retained and wil trade on NASDAQ
